VALUE CHAIN INSIGHTS

VALUE CHAIN INSIGHTS

  • Posted in: Value Chain Insights

    Contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) have been ...

  • Posted in: Value Chain Insights

    Emerging pharma companies are an important source of innovation for the pharmaceutical industry, but how is this sector ...

  • Posted in: Value Chain Insights

    How can pharmaceutical companies take sourcing, procurement, and supply management to the next level?. Pharmaceutical ...

  • Posted in: Value Chain Insights

    At a recent Congressional hearing, representatives from the FDA and the Association for Accessible Medicines (formerly ...

  • Posted in: Value Chain Insights

    Driven by new product development for biopharmaceuticals, contract manufacturing organizations (CMOs) are expanding. So ...

  • Posted in: Value Chain Insights

    As pharmaceutical companies intensify their product development in biologics, their supply requirements increase as well. ...

  • Posted in: Value Chain Insights

    In what segments are contract manufacturers expanding development and manufacturing capabilities? DCAT Value Chain Insights ...

  • Posted in: Value Chain Insights

    The Biosimilars Council, a division of the Association for Accessible Medicines (formerly the Generic Pharmaceutical ...

  • Posted in: Value Chain Insights

    Pharmaceutical companies, CDMOs, CMOs, and excipient producers need to continually evaluate their strategies, technologies, ...

  • Posted in: Value Chain Insights

    Potential mega-mergers put Pfizer in the headlines over the past several years, but will that be the strategy of the ...

  • Posted in: Value Chain Insights

    Trade is a large issue in current public policy debates, particularly with the new US Presidential Administration. So what ...

  • Posted in: Value Chain Insights

    Effective communication is an imperative for successful business relationships, but are you sending the right signals ...

  • Posted in: Value Chain Insights

    In the battle of small molecules versus biologics, how have new small molecules fared? DCAT Value Chain Insights examines ...

  • Posted in: Value Chain Insights

    Are pharmaceutical companies outsourcing more of their development and manufacturing activities, and what can be expected ...

  • What is Next for Teva?

    Posted in: Value Chain Insights

    Teva Pharmaceutical Industries announced this week that its current chief executive, Erez Vigodman, was stepping down ...

  • Posted in: Value Chain Insights

    With the rise of biologic-based drug development, the number of parenteral drugs under development and receiving approval ...

  • Posted in: Value Chain Insights

    A recent PwC study of nearly 1,400 CEOs asked for their input on the impact of globalization and technology on business ...

  • Posted in: Value Chain Insights

    So how will the pharmaceutical industry fare in 2017 and beyond? A DCAT Week '17 education program, Pharma Industry ...

  • Posted in: Value Chain Insights

    Using a risk-based inspection scheme, the US Food and Drug Administration has made bringing to parity inspections of ...

  • Posted in: Value Chain Insights

    Blockchain technology has all the buzz in the banking and financial services industries, but does it have potential for ...

  • Posted in: Value Chain Insights

    Health ministers from more than 35 countries of the Organisation for Economic Co-operation and Development (OECD) met this ...

  • Posted in: Value Chain Insights

    From healthcare reform, to slowing global pharmaceutical industry growth, to a possible showdown in biosimilars, DCAT ...

  • Posted in: Value Chain Insights

    Following two consecutive years of high numbers in new molecular entity (NME) approvals by the US Food and Drug Administrations ...

  • Posted in: Value Chain Insights

    Total spending on medicines is forecast to reach $1.5 trillion by 2021, up 33% from 2016 levels even as annual growth ...

  • Posted in: Value Chain Insights

    A recent study by A.T. Kearney provides benchmarks for a proprietary metric, return on supply management assets, and ...

  • Posted in: Value Chain Insights

    The FDA has issued final guidance regarding implementation of the Drug Supply Chain Security Act (DSCSA), legislation ...

  • Posted in: Value Chain Insights

    As 2016 comes to a close, what have been the top stories of 2016 thus far? DCAT Value Chain Insights (VCI) examines ...

  • Posted in: Value Chain Insights

    Johnson & Johnson (J&J) has confirmed that it is in preliminary discussions with Actelion Pharmaceuticals, an Allschwil, ...

  • Posted in: Value Chain Insights

    Data and the analysis of that data guide drug development, product decisions, dosing and patient use, and pricing and ...

  • Posted in: Value Chain Insights

    Gilead Sciences rose to the top of the pharmaceutical industry company rankings on the strength of its hepatitis C franchise, ...

  • Posted in: Value Chain Insights

    Patent pendency, the time it takes for patent review and approval, is an important measure of innovation, and significant ...

  • Posted in: Value Chain Insights

    As the number of and diversity of drug candidates enter pharmaceutical companies' pipelines, strategies to overcome issues ...

  • Posted in: Value Chain Insights

    Much attention has been given to personalized medicines as a means of transforming healthcare with potentially more effective ...

  • Posted in: Value Chain Insights

    Orphan drugs have dominated new drug approvals over the past several years, but are they delivering market success? Facing ...

  • Posted in: Value Chain Insights

    A recent benchmarking analysis by The Hackett Group outlines the performance advantages of world-class procurement organizations. ...

  • Posted in: Value Chain Insights

    While most industry analysis touts the importance of digital technologies in meeting business goals, has this really ...

  • Posted in: Value Chain Insights

    Overall venture-capital (VC) activity declined in the third quarter of 2016, both in the number of deals and in dollars, ...

  • Posted in: Value Chain Insights

    Stefan Oschmann, chairman of the Executive Board and CEO of Merck KGaA, recently outlined the company's progress in meeting ...

  • Posted in: Value Chain Insights

    Small molecules are the dominant modality for active pharmaceutical ingredients (APIs), an important measure for fine ...

  • Posted in: Value Chain Insights

    Regulatory agencies in the US, European Union, and Japan are moving forward with plans to achieve greater cooperation ...

  • Posted in: Value Chain Insights

    Pfizer announced this week that the company will not pursue separating the company into two independent companies, one ...

  • Posted in: Value Chain Insights

    Following its proposed $66-billion acquisition of the agrochemical and seeds company, Monsanto, Bayer has reaffirmed ...

  • Posted in: Value Chain Insights

    GlaxoSmithKline's (GSK) has announced that Emma Walmsley, currently chief executive officer (CEO) of GSKs Consumer Healthcare ...

  • Posted in: Value Chain Insights

    Diabetes is the second largest therapeutic sector among developed countries, trailing only oncology. So how are the pharmaceutical ...

  • Posted in: Value Chain Insights

    Editor's Note: This article was updated to reflect further developments from September 2016 to end of November 2016. ...

  • Posted in: Value Chain Insights

    The US Food and Drug Administrations (FDA) Center for Drug Evaluation and Research (CDER) has approved 16 new molecular ...

  • Posted in: Value Chain Insights

    Oncology is the largest therapeutic sector in the global pharmaceutical industry, accounting for nearly $105 billion ...

  • Posted in: Value Chain Insights

    Pfizer has agreed to acquire Medivation, a pharmaceutical company specializing in small-molecule oncology drugs, for ...

  • Posted in: Value Chain Insights

    The International Chamber of Commerce and the UN Global Compact recently formed a partnership to improve awareness, opportunities, ...

  • Posted in: Value Chain Insights

    From 3-D printing, to non-oral delivery of biologics, to advances in nanotechnology, the future for drug delivery is ...

  • Posted in: Value Chain Insights

    Orphan drugs have dominated new drug approvals over the past several years, but have they been met with commercial success? ...

  • Posted in: Value Chain Insights

    Manufacturing issues and a limited number of suppliers contributed to drug shortages for generic sterile injectable drugs, ...

  • Posted in: Value Chain Insights

    A recent analysis by Deloitte Consulting gained feedback from chief executive officers (CXOs) and chief executives-in-waiting ...

  • Posted in: Value Chain Insights

    The US Food and Drug Administration (FDA) will hold a public meeting on August 15, 2016, to discuss proposed recommendations ...

  • Posted in: Value Chain Insights

    The policy direction of the pharmaceutical industry in the UK in the wake of Brexit took another turn when the UK Life ...

  • Posted in: Value Chain Insights

    Given the high cost of new drug development, pharmaceutical companies, researchers, and other organizations are looking ...

  • Posted in: Value Chain Insights

    So what have been the pressing developments in the pharmaceutical manufacturing value chain thus far this year? DCAT ...

  • Posted in: Value Chain Insights

    The United Kingdom’s decision to exit the European Union (EU) via a majority vote in a public referendum has created ...

  • Posted in: Value Chain Insights

    A recent analysis by KPMG points out that disruptive factors, such as new technologies, increasing competition, and pricing ...

  • Posted in: Value Chain Insights

    How pharmaceutical companies and CDMOs, CMOs, and suppliers collaborate is a key factor in being able to meet goals for ...

  • Posted in: Value Chain Insights

    Is your company properly aligned to manage risk? A recent analysis by PwC provides insight on the key characteristics ...

  • Posted in: Value Chain Insights

    The US and Europe biotechnology industries set highs in key areas, such as revenue, net income, financing, and deal values ...

  • Posted in: Value Chain Insights

    Sanofi CEO Olivier Brandicourt is pushing hard to acquire the biopharmaceutical company, Medivation, as Sanofi moves ...

  • Posted in: Value Chain Insights

    In what ways are pharmaceutical companies changing their expectations of suppliers? How can CDMOs, CMOs, and suppliers ...

  • Posted in: Value Chain Insights

    Growth in global spending on oncology therapeutics and supportive care drugs increased 11.5% on a constant-dollar basis ...

  • Posted in: Value Chain Insights

    Expansions in biologics manufacturing continue to dominate the capital expenditures of the pharmaceutical majors. So ...

  • Posted in: Value Chain Insights

    Biosimilars are a niche sector of the overall pharmaceutical market, but as the regulatory pathway becomes more defined ...

  • Posted in: Value Chain Insights

    The shareholders of Baxalta and Shire have approved the companies’ $32 billion merger with the deal now expected to close ...

  • Posted in: Value Chain Insights

    How can pharmaceutical companies and suppliers move beyond traditional paradigms in sourcing and procurement and advance ...

  • Posted in: Value Chain Insights

    At a recent investors' presentation, Eli Lilly and Company outlined its plan to potentially launch 20 new products through ...

  • Posted in: Value Chain Insights

    A recent study by A.T. Kearney identifies 12 macro trends that will play a major role in the current and future operating ...

  • Posted in: Value Chain Insights

    Having successfully floated its material sciences business, Covestro, Bayer is now positioned as a pure-play life sciences ...

  • Posted in: Value Chain Insights

    How do Procurement organizations of the large and mid-size pharmaceutical and biopharmaceutical companies measure up in ...

  • Posted in: Value Chain Insights

    Solid dosage products are a mainstay of new drug development, but parenteral drug development is on the rise. So which ...

  • Posted in: Value Chain Insights

    A recent report by the Office of the US Trade Representative highlights challenges in intellectual property rights protection ...

  • Posted in: Value Chain Insights

    The resurgence of the US pharmaceutical market is the key story in the global pharmaceutical market as the fortunes of ...

  • Posted in: Value Chain Insights

    For the pharmaceutical industry and other industrial sectors, deciding where to locate manufacturing facilities is a crucial ...

  • Posted in: Value Chain Insights

    The departure of Perrigo chairman and CEO Joseph Papa comes six months after the company successfully defended a $26 billion ...

  • Posted in: Value Chain Insights

    High-potency manufacturing continues to attract the investment dollars of CDMOs and CMOs. So what are the key projects? ...

  • Posted in: Value Chain Insights

    Total spending on medicines in the US reached $310 billion in 2015 on an estimated net price basis, up 8.5% from the ...

  • Posted in: Value Chain Insights

    Some 30 companies are actively developing biosimilar medicines for launch and are pursuing biosimilar versions of 16 ...

  • Posted in: Value Chain Insights

    A recent industry study examines the extent to which the public investment, intellectual property, and drug pricing policies ...

  • Posted in: Value Chain Insights

    Pfizer and Allergan have called off their proposed $160 billion merger citing the US Department of Treasury’s issuance ...

  • Posted in: Value Chain Insights

    By Andrew Turley, European Correspondent for DCAT Value Chain Insights (VCI) A key upcoming deadline in 2018 ...

  • Posted in: Value Chain Insights

    From tracking pharmaceutical industry growth patterns to evaluating sourcing and supply strategies for small molecules, ...

  • Posted in: Value Chain Insights

    Aprecia Pharmaceuticals has become the first company to commercially launch a FDA-approved drug manufactured using 3-D ...

  • Posted in: Value Chain Insights

    GlaxoSmithKline's (GKS) CEO Sir Andrew Witty has announced his intention to retire from the company in early 2017. The ...

  • Posted in: Value Chain Insights

    Looking back at 2015, which potential blockbusters have made the mark and remain poised for commercial success? DCAT ...

  • Posted in: Value Chain Insights

    What are the blockbusters of the future? A recent industry analysis points to the leading contenders anticipated for market ...

  • Posted in: Value Chain Insights

    What are the major regulatory changes impacting active pharmaceutical ingredient (API) manufacturing and what is the ...

  • Posted in: Value Chain Insights

    What are the major company developments impacting the pharmaceutical manufacturing value chain? DCAT's Member Company ...

  • Posted in: Value Chain Insights

    Information technology has always been important for executing sourcing and Procurement functions. But as pharmaceutical ...

  • Posted in: Value Chain Insights

    What is the optimal approach for pharmaceutical development and manufacturing? An upcoming DCAT Week '16 education program ...

  • Posted in: Value Chain Insights

    A recent analysis by the US Government Accountability Office (GAO) examined how companies are complying with US Securities ...

  • Posted in: Value Chain Insights

    Chemicals play an important part in the pharmaceutical manufacturing value chain. So what were the key issues driving ...

  • Posted in: Value Chain Insights

    A recent executive study puts risk management as a key component of overall corporate strategy. So where are companies ...

  • Posted in: Value Chain Insights

    As the number of biologic-based drugs in development and commercialization grows, a crucial issue for the industry is ...

  • Posted in: Value Chain Insights

    The pharmaceutical industry is part of the overall ecosystem for healthcare, so what key trends and issues in healthcare ...

  • Posted in: Value Chain Insights

    So what lies ahead for the generic drug market? DCAT Value Chain Insights (VCI) examines the market and upcoming regulatory ...

  • Posted in: Value Chain Insights

    Reshoring has been the talk for US manufacturing. But what do the data show? A recent analysis by A.T. Kearney ...

  • Posted in: Value Chain Insights

    Orphan drugs accounted for nearly half of new molecular entities (NMEs) approved by the FDA in 2015. Is this a winning ...

  • Posted in: Value Chain Insights

    At a recent investors' conference Ian Read, chairman and CEO of Pfizer, and Brent Saudners, CEO and president of Allergan, ...

  • Posted in: Value Chain Insights

    A recent analysis, the MoneyTree Report by PricewaterhouseCoopers and the National Venture Capital Association based ...

  • Posted in: Value Chain Insights

    Shire's proposed $32 billion acquisition of Baxalta, the biopharmaceutical company spun off from Baxter in 2015, would ...

  • Posted in: Value Chain Insights

    In 2015, the US Food and Drug Administration's Center for Drug Evaluation and Research approved 45 new molecular entities ...

  • Posted in: Value Chain Insights

    Patient adherence is an important consideration when designing drug-delivery systems, devices, and related components ...

  • Posted in: Value Chain Insights

    So what is on the horizon for the pharmaceutical industry for 2016? DCAT Value Chain Insights (VCI) highlights 10 key ...

  • Posted in: Value Chain Insights

    Just weeks after Pfizer and Allergan announced a $160 billion mega merger, the supply side is bracing for its mega deal: ...

  • Posted in: Value Chain Insights

    As 2015 comes to a close, a crucial question for procurement organizations is how they performed in 2015 in delivering ...

  • Posted in: Value Chain Insights

    As 2015 begins to wind down, the US Food and Drug Administration's Center for Drug Research and Evaluation has approved ...

  • Posted in: Value Chain Insights

    The IMS Institute for Healthcare Informatics projects that total spending on medicines will reach $1.4 trillion by 2020 ...

  • Posted in: Value Chain Insights

    As we begin the final month of 2015, what have been the top stories of 2015 thus far? DCAT Value Chain Insights (VCI) ...

  • Posted in: Value Chain Insights

    Pfizer's pending $160 billion acquisition of Allergan would be the largest deal in pharmaceutical industry history, so ...

  • Posted in: Value Chain Insights

    After Mylan failed to secure the necessary shares for its proposed $26 billion takeover of Perrigo last week, what is ...

  • Posted in: Value Chain Insights

    Roche's announcement last week that it plans to close four small-molecule manufacturing facilities is the latest move ...

  • Posted in: Value Chain Insights

    The US Federal Trade Commission (FTC) is among those asking the US Food and Drug Administration (FDA) to reconsider its ...

  • Posted in: Value Chain Insights

    Sanofi CEO Olivier Brandicourt has put forth a plan to refocus and reshape Sanofi with the goal of generating compound ...

  • Posted in: Value Chain Insights

    Shire's proposed $5.9 billion acquisition of Dyax, a company specializing in drug development for rare diseases, is the ...

  • Posted in: Value Chain Insights

    Pfizer and Allergan have confirmed that the companies are in preliminary friendly discussions in relation to a potential ...

  • Posted in: Value Chain Insights

    Despite increased penetration of biologics and small-molecules delivered via parenterally or in other routes, solid dosage ...

  • Posted in: Value Chain Insights

    The European Medicines Agency (EMA) issued a report to highlight the agency's work, including inspections of good manufacturing ...

  • Posted in: Value Chain Insights

    The Trans-Pacific Partnership (TPP) agreement has engendered debate with the pharmaceutical industry as the industry ...

  • Posted in: Value Chain Insights

    Supplier-led innovation is an important part of building strategic partnerships. GlaxoSmithKline is among the companies ...

  • Posted in: Value Chain Insights

    Small molecules still constitute the majority of commercial drugs, but biologics' inroads into the pharmaceutical market ...

  • Posted in: Value Chain Insights

    Merck KGaA is using internal investment, alliances, and mergers and acquisitions as a means to grow two of its major ...

  • Posted in: Value Chain Insights

    The International Conference on Harmonization (ICH) is an important mechanism for facilitating harmony in pharmaceutical ...

  • Posted in: Value Chain Insights

    The US Food and Drug Administration (FDA) has approved 27 new molecular entities thus far in 2015, with five NME approvals ...

  • Posted in: Value Chain Insights

    Although continuous manufacturing is common in other industrial production, such as food processing and petrochemicals, ...

  • Posted in: Value Chain Insights

    A recent study from the IMS Institute for Healthcare Informatics estimates there are now more than 165,000 mobile health ...

  • Posted in: Value Chain Insights

    Having the right governance model for external partnerships is critical for a successful outsourcing relationship. So ...

  • Posted in: Value Chain Insights

    Partnerships are a mainstay in drug development, but the pharmaceutical industry is entering into a new era of innovation ...

  • Posted in: Value Chain Insights

    Immuno-oncology is a hot area in the pharmaceutical market, led by recent potential blockbuster product introductions ...

  • Posted in: Value Chain Insights

    Paul M. Bisaro, executive chairman and Brent Sanders, CEO and president, are leading Allergan through its transformation ...

  • Posted in: Value Chain Insights

    From new approaches for patient adherence, to advances in anti-counterfeiting technology, and innovation in for protecting ...

  • Posted in: Value Chain Insights

    The US Food and Drug Administration (FDA) held a public meeting in late August to gain feedback on its proposed quality ...

  • Posted in: Value Chain Insights

    The OTC market is coming off an active year in 2014 and 2015 to date, which included two mega deals: the formation of ...

  • Posted in: Value Chain Insights

    Growth in the injectables market is being driven by generic injectables, which are outpacing growth of innovator injectables ...

  • Posted in: Value Chain Insights

    Successful supplier relationships are crucial for executing a company’s overall business strategy. How does the pharmaceutical ...

    1 person recommends this.
  • Posted in: Value Chain Insights

    What are key recent events that may foreshadow significant change in the pharmaceutical industry? A recent IMS report ...

  • Posted in: Value Chain Insights

    Bayer AG is proceeding with a strategy to demerge its material sciences business to become a pure-play life sciences company ...

  • Posted in: Value Chain Insights

    Shire's $30 billion proposal to acquire Baxalta, the newly spun-off company from Baxter Healthcare, would give Shire a ...

  • Posted in: Value Chain Insights

    What are the blockbusters of the future? A recent industry analysis points to the leading contenders from late-stage or ...

  • Posted in: Value Chain Insights

    A rebound in the US market, driven by specialty sales, and emerging-market volume growth are driving pharmaceutical industry ...

  • Posted in: Value Chain Insights

    Approvals and advisory committee recommendations last week by the US Food and Drug Administration and the European Medicines ...

  • Posted in: Value Chain Insights

    Teva Pharmaceutical Industries has dropped its pursuit of Mylan N.V. and instead has made a $40.5 billion offer to acquire ...

  • The Ascent of Celgene

    Posted in: Value Chain Insights

    Celgene's $7.2 billion bid to acquire the biopharmaceutical company Receptos is the latest move by the company as it seeks ...

  • Posted in: Value Chain Insights

    Clinical trial material supply is an integral part of the supply strategy of pharmaceutical companies. As the number of ...

  • Posted in: Value Chain Insights

    The pharmaceutical majors are rolling out new initiatives to meet corporate sustainability goals with environmental, health, ...

  • Posted in: Value Chain Insights

    The US House of Representatives has approved the 21st Century Cures Act, a bill that increases funding to the National ...

  • Posted in: Value Chain Insights

    Baxalta, the newly spun-off company from Baxter Healthcare, has launched as a new separate, independent $6 billion biopharmaceutical ...

  • Posted in: Value Chain Insights

    What countries rank the highest and lowest for biopharmaceutical competitiveness? Where are companies investing in research ...

    1 person recommends this.
  • Posted in: Value Chain Insights

    So what have the been most noteworthy mergers and acquisitions (MA&) thus far in 2015? DCAT Value Chain Insights (VCI) ...

  • Posted in: Value Chain Insights

    The US Food and Drug Administration has approved 14 new molecular entities thus far in 2015. So which are the most promising ...

  • Posted in: Value Chain Insights

    Following the closing of its three-part transaction with GlaxoSmithKline and the divestiture of its animal health business ...

  • Posted in: Value Chain Insights

    The Drug Supply Chain Security Act (DSCSA) outlines critical steps to build an electronic, interoperable system to identify ...

  • Posted in: Value Chain Insights

    A recent report by the US General Accounting Office (GAO) was critical over the lack of coordination between the US Food ...

  • Posted in: Value Chain Insights

    The global biotechnology industry set records in several financial metrics in 2014 and reached an historical first, $1 ...

  • Posted in: Value Chain Insights

    The recent decision by the US National Institutes of Health (NIH) to suspend sterile manufacturing in its pharmaceutical ...

  • Posted in: Value Chain Insights

    Patheon's announcement this week that it plans to file for an initial public offering (IPO) is the latest move by the ...

  • Posted in: Value Chain Insights

    The annual meeting of the American Society of Clinical Oncology (ASCO) is an important event for pharmaceutical companies ...

  • Posted in: Value Chain Insights

    Marijn Dekkers, Bayer's Management Board Chairman and CEO, recently outlined the company's progress in demerging its material ...

  • Posted in: Value Chain Insights

    Pharmaceutical companies and suppliers face critical issues as they seek to optimize their manufacturing supply chains, ...

  • Posted in: Value Chain Insights

    Risk management is on the agenda of CEOs across all industries, but what do they perceive as threats and what measures ...

  • Posted in: Value Chain Insights

    Venture capital funding is an important measure of the health of emerging biopharmaceutical companies. A recent PwC study ...

  • Posted in: Value Chain Insights

    At a meeting last week with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson ...

  • Posted in: Value Chain Insights

    The IPEC Federation has issued a position paper on European Union (EU) guidelines for excipients based on quality risk ...

  • Posted in: Value Chain Insights

    Is the US Food and Drug and Administration achieving parity in inspections of foreign and domestic manufacturers? A recent ...

  • Posted in: Value Chain Insights

    In the latest deal in the specialty pharmaceuticals market, Endo International has agreed to acquire Par Pharmaceutical ...

  • Posted in: Value Chain Insights

    The global oncology market is the largest therapeutic area overall and in developed markets. In 2014, this segment reached ...

  • Posted in: Value Chain Insights

    Risk management is a crucial part of any company's strategic and operational focus. But how does it impact the bottom ...

  • Posted in: Value Chain Insights

    So how did the pharmaceutical majors fare in the first quarter and what are the key product and pipeline developments? ...

  • Posted in: Value Chain Insights

    The global generic-drug market is undergoing change as consolidation looms among the top players and gains from recent ...

  • Posted in: Value Chain Insights

    The rankings of the top global pharmaceutical companies and products are undergoing change as mergers and acquisitions, ...

  • Posted in: Value Chain Insights

    Spending on medicines reached $373.9 billion in the US in 2014, up 13.1% year over year, the highest growth level since ...

  • Posted in: Value Chain Insights

    Teva Pharmaceutical Industries Ltd. has announced a proposal to acquire all of the outstanding shares of Mylan N.V. in ...

  • Posted in: Value Chain Insights

    Led by growth in the oncology sector, high-potency manufacturing continues to be an area of investment for contract manufacturers ...

  • Posted in: Value Chain Insights

    Last year was a strong year for the US and European biotechnology sectors, led by a resurgence in initial public offerings ...

  • Posted in: Value Chain Insights

    Mylan's $28.9 billion proposal to acquire Perrigo would create a company with a focus on specialty brands, generics, over-the-counter, ...

  • Posted in: Value Chain Insights

    Supply chains are highly complex and are continuously exposed to a variety of internal and external risks. Whether today’s ...

  • Posted in: Value Chain Insights

    The approval of the first biosimilar in the US last month was only the beginning in the biosimilars market. Reimbursement ...

  • Posted in: Value Chain Insights

    Valeant Pharmaceuticals International, Inc. has completed its previously announced acquisition of the specialty pharmaceutical ...

  • Posted in: Value Chain Insights

    The approval of Sandoz's Zarxio, a biosimilar of filgrastim, the active ingredient in Amgen's Neupogen, in early March ...

  • Posted in: Value Chain Insights

    A rebound in the US market, driven by specialty sales, and emerging-market volume growth are driving pharmaceutical industry ...

  • Posted in: Value Chain Insights

    DCAT Week '15 provided key insights in the global pharmaceutical industry and supply strategies for small molecules and ...

    1 person recommends this.
  • Posted in: Value Chain Insights

    What are the blockbusters of the future? A recent industry analysis points to the leading contenders from late-stage or ...

  • Posted in: Value Chain Insights

    How will energy costs influence the market for chemical commodities and downstream products? What will be the impact ...

  • Posted in: Value Chain Insights

    Solid dosage products are a mainstay of the pharmaceutical market. Despite increased penetration of biologics and small-molecules ...

    1 person recommends this.
  • Posted in: Value Chain Insights

    AbbVie's proposed $21 billion acquisition of Pharmacyclics is the latest effort by AbbVie to diversify its product portfolio ...

  • Posted in: Value Chain Insights

    Biologics manufacturing is an active area of investment by the large pharmaceutical companies. DCAT Value Chain Insights ...